Last reviewed · How we verify
Myeloma Immunoglobulin Idiotype Vaccine-KLH
Myeloma Immunoglobulin Idiotype Vaccine-KLH is a Cancer vaccine Small molecule drug developed by National Cancer Institute (NCI). It is currently in Phase 3 development for Multiple myeloma (personalized idiotype vaccine).
This vaccine trains the immune system to recognize and attack cancer cells by targeting the unique protein signature (idiotype) present on individual myeloma tumors.
This vaccine trains the immune system to recognize and attack cancer cells by targeting the unique protein signature (idiotype) present on individual myeloma tumors. Used for Multiple myeloma (personalized idiotype vaccine).
At a glance
| Generic name | Myeloma Immunoglobulin Idiotype Vaccine-KLH |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Drug class | Cancer vaccine |
| Target | Myeloma immunoglobulin idiotype (patient-specific) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The vaccine is personalized for each patient, using their myeloma's unique immunoglobulin idiotype conjugated to keyhole limpet hemocyanin (KLH) as an immunogenic carrier. This approach stimulates both cellular and humoral immune responses against the patient's own malignant plasma cells. By targeting the idiotype—a tumor-associated antigen unique to each patient's myeloma—the vaccine aims to induce durable anti-tumor immunity while minimizing off-target effects.
Approved indications
- Multiple myeloma (personalized idiotype vaccine)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Vaccine Therapy in Treating Patients With Multiple Myeloma (PHASE2)
- Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant (PHASE2)
- Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation (PHASE1)
- Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma (PHASE2)
- Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma (PHASE1)
- Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Myeloma Immunoglobulin Idiotype Vaccine-KLH CI brief — competitive landscape report
- Myeloma Immunoglobulin Idiotype Vaccine-KLH updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about Myeloma Immunoglobulin Idiotype Vaccine-KLH
What is Myeloma Immunoglobulin Idiotype Vaccine-KLH?
How does Myeloma Immunoglobulin Idiotype Vaccine-KLH work?
What is Myeloma Immunoglobulin Idiotype Vaccine-KLH used for?
Who makes Myeloma Immunoglobulin Idiotype Vaccine-KLH?
What drug class is Myeloma Immunoglobulin Idiotype Vaccine-KLH in?
What development phase is Myeloma Immunoglobulin Idiotype Vaccine-KLH in?
What are the side effects of Myeloma Immunoglobulin Idiotype Vaccine-KLH?
What does Myeloma Immunoglobulin Idiotype Vaccine-KLH target?
Related
- Drug class: All Cancer vaccine drugs
- Target: All drugs targeting Myeloma immunoglobulin idiotype (patient-specific)
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma (personalized idiotype vaccine)